STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...

RNA plays critical roles in nearly all biological processes, but current methods for sequencing RNA are significantly limited. This is partially because RNA molecules are chemically modified within ...

The genetic modification therapy market presents key opportunities in developing specialized treatments for rare, inherited, ...

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, ...

< Photo 1. (From left) Professor Won Do Heo and Jihwan Yu, a Ph.D. Candidate of the Department of Biological Sciences > CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

Advancing RNA therapeutics depends on understanding two critical questions: Where do drug candidates go, and what do they do ...

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Alida Biosciences, a leader in next-generation RNA modification analysis, is proud to announce its first official service provider: the Genomic and RNA ...

The innate immune system is the body's first line of defense against pathogens and foreign substances. An essential component of this system are pattern recognition receptors, which recognize non-self ...